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A B S T R A C T
Signaling by mammalian target of rapamycin (mTOR), a kinase regulator of protein synthesis, has been im-
plicated in the development of chronic pain. The mTOR comprises two distinct protein complexes, mTOR
complex 1 (mTORC1) and mTORC2. Although effective inhibitors of mTORC1 and C2 have been developed,
studies on the effect of these inhibitors related to pain modulation are still lacking. This study was conducted to
determine the inhibitory effects of Torin1 and XL388 in an animal model of neuropathic pain. Seven days after
neuropathic surgery, Torin1 or XL388 were microinjected into the insular cortex (IC) of nerve-injured animals
and behavioral changes were assessed. Administration of Torin1 or XL388 into the IC significantly increased
mechanical thresholds and reduced mechanical allodynia. At the immunoblotting results, Torin1 and XL388
significantly reduced phosphorylation of mTOR, 4E-BP1, p70S6K, and PKCα, without affecting Akt. These results
strongly suggest that Torin1 and XL388 may attenuate neuropathic pain via inhibition of mTORC1 and mTORC2
in the IC.
1. Introduction
Pain signals transmitted via nociceptive neurons are comprehen-
sively projected to several brain regions [1,2]. The insular cortex (IC),
one of the pain-related brain regions, can be activated upon nociceptive
stimulation and is associated with pain memory and emotional pro-
cessing of pain [3]. Several studies have shown that neural plasticity
also forms in the IC under conditions of neuropathic pain [3–5]. For
example, pain behaviors were diminished when blocking protein kinase
Mζ, a key factor in maintaining long-term potentiation (LTP) in the IC
[6].
Our previous report demonstrated that neural plasticity could be
induced by nerve injury and altered through mTOR modulation in the
IC [7]. Mammalian target of rapamycin (mTOR) is a protein serine/
threonine kinase that regulates cell proliferation, cell growth, motility,
and cell survival [8]. It serves as an integral component of two com-
plexes, mTOR complex (mTORC) 1 and mTORC2 (mTORC1/2) [9–11].
Active mTORC1 phosphorylates downstream effectors such as eu-
karyotic translation initiation factor 4E binding protein 1 (4E-BP1) and
p70 ribosomal S6 kinase (p70S6K), which serve as crucial factors in the
initiation of mRNA translation [12–14]. Downstream effectors of
mTORC2 include protein kinase B (Akt/PKB) and protein kinase C
alpha (PKCα), which play a role in cell survival, cytoskeletal re-
arrangement, and actin regulation [15].
The mTORC1-blocking allosteric mTOR inhibitors, including rapa-
mycin, rapalogs, and their derivatives, have been widely studied in
oncogenic research owing to their efficacy and limited side effects
[5–7]. Recently, it has been studied that mTOR inhibitors may affect
cancer-related pain, in addition to inhibiting cancer itself [16,17].
Furthermore, mTOR inhibitors have also been studied in relation to
inflammatory pain and neuropathic pain [8,9]. The association be-
tween mTOR signaling and neuropathic pain is still being investigated
in animal studies [4,10,11]. However, inhibiting only mTORC1 acti-
vates the feedback loop associated with the mTOR pathway and makes
it difficult to complete suppression of the mTOR complex [18]. Con-
sequently, several drugs targeting both mTOR complexes, such as the
ATP-competitive mTOR inhibitor and dual phosphatidylinositol 3-ki-
nase (PI3K)/mTOR inhibitor, are currently under development [18,19].
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Torin1 and XL388 are newly developed ATP-competitive inhibitors that
suppress the activation of both mTOR complexes [20–22]. A few studies
have confirmed the pain relieving effect of novel mTOR inhibitors,
which have been improved over rapamycin and rapalogs in the spinal
cord [23,24]. However, there has been no report about attenuating pain
via direct injection of these novel mTOR inhibitors into the parenchyma
of the brain.
The pain attenuating effect of simultaneous inhibition of the two
mTOR complexes in the IC was not investigated so far. Therefore, this
study was conducted to assess the pain alleviation effects of Torin1 and
XL388 by direct administration into the IC. Specifically, we assessed the
phosphorylation levels of mTOR and of the respective downstream ef-
fectors in the IC following Torin1 or XL388 administration. The findings
of this study may provide the potential therapeutic intervention for
pain management using mTORC1/2 inhibition.
2. Materials and methods
2.1. Experimental animals
All experimental procedures adhered to the guidelines of the
National Institute of Health, and were approved by the Institutional
Animal Care and Use Committee of Yonsei University Health System
(permit no. 2017-0148). Male Sprague-Dawley rats (200−250 g;
Harlan, Koatec, Pyeongtaek, Korea) were used for all experiments.
2.2. Cannula implantation
Rats were anesthetized with sodium pentobarbital (50mg/kg, i.p.)
for deep anesthesia and placed in a stereotaxic frame (David KOPF
instruments, Los Angeles, CA, U.S.A.). After local anesthesia with li-
docaine to minimize the pain from surgery, the scalp was cut to expose
the bregma. The guide cannulae (28-gauge) were bilaterally implanted
into the rostral anterior IC (anterior: 1.0 mm from bregma; lateral: ±
4.9 mm from the midline; depth: -5.9 mm from the surface of the skull).
The cannulae were fixed to the bone with dental cement, and the
dummy cannulae were inserted into the guide cannulae to prevent
clogging caused by coagulation.
2.3. Neuropathic surgery
Neuropathic surgery was conducted as described previously [25]
following a 7-day recovery period after cannula implantation. Rats
were reanesthetized with isoflurane using a 5 % vaporizer prior to
neuropathic surgery. The tibial and sural nerves were tightly ligated
with 5-0 black silk and sectioned distal to the ligation, whereas the
common peroneal nerve was left intact. Rats in the sham group were
subjected to the same surgical procedure for exposing the sciatic nerve,
without the injury procedure.
2.4. Mechanical allodynia assessment
To assess changes in the mechanical threshold, the mechanical al-
lodynia test was performed one day prior to nerve injury and on post-
operative days (PODs) 1, 4, and 7. On POD 7, additional behavioral
tests were performed from 30min up to 48 h following microinjection.
Each rat was habituated for 15min in an acrylic cage. The mechanical
allodynia test was performed using an electronic von Frey filament (no.
38450; UGO Basile, Varese, Italy). The measurements were repeated
seven times at 2- to 3-min intervals, and the data were averaged, ex-
cluding the maximum and minimum values.
2.5. Microinjection of Torin1 and XL388 into the IC
All injected solutions were saline-based and contained 0.06 %
DMSO. Torin1 (Tocris Bioscience, Bristol, UK.) and XL388 (Tocris
Bioscience) were diluted in base solution at 400 nM and 500 nM, re-
spectively. These doses of Torin1 and XL388 were used as the optimal
concentration for our experiment, in accordance with previous studies
[20,26]. The vehicle, Torin1, or XL388 was injected into the IC bilat-
erally at the same rate of 0.5 μl/min. After the microinjection, the in-
jection cannula was placed additional 1min to minimize reflux along
the cannula.
2.6. Western blot analysis
On POD7, targeted IC regions were collected 4 h after microinjec-
tion and immediately frozen in liquid nitrogen and stored at −70 °C.
For protein extraction, phosphatase inhibitors (PhosSTOP; Roche,
Mannheim, Germany) were added to the lysis buffer (PRO-PREP; Intron
Biotechnology, Pyeongtaek, Korea) and samples were homogenized and
centrifuged at 15,000 rpm for 10min. Protein samples were denatured
and separated then transferred onto a membrane (Merck Millipore,
Darmstadt, Germany). The membrane was incubated in a 5 % bovine
serum albumin solution for 1 h at room temperature, and then in-
cubated with primary antibody overnight at 4 °C. The following pri-
mary antibodies were used : mTOR (1:500 dilution; no.2972), p-mTOR
(1:500; no.2971), p70S6K (1:1000; no.2708), p-p70S6K (1:500;
no.9205), 4E-BP1 (1:1000; no.9644), p-4E-BP1 (1:500; no.2855), Akt
(1:3000; no.4691) and p-Akt (1:1000; no.4058) antibodies were from
Cell Signaling Technology (Beverly, MA, USA); PKCα (1:1000; ab4124)
and p-PKCα (1:1000; ab23512) antibodies were from Abcam
(Cambridge, UK); β-actin (1:15,000; LF-PA0207) was from ABFrontier
(Seoul, Korea). The membrane was then incubated with secondary anti-
rabbit antibody (1:5000; no.7074, CST) for 2 h at 20 °C. Six animals per
group were used for western blot analysis. Samples of each group were
pooled and replicated more than four times. The band intensity was
quantified using the LAS system (LAS 4000, Fuji Film Inc., Tokyo,
Japan). β-actin was used as an internal loading control.
2.7. Statistical analyses
Statistical analyses were performed using the SPSS 20.0 software
(IBM Corporation, Armonk, NY, USA). Behavioral data were analyzed
using a two-way repeated measures ANOVA followed by the
Bonferroni’s post-hoc multiple comparison test. Western blotting data
were analyzed using a one-way ANOVA followed by Bonferroni’s post-
hoc multiple comparison test. All values are expressed as mean ±
standard error of the mean (SEM). P values less than 0.05 were con-
sidered statistically significant.
3. Results
3.1. Nerve injury induces mechanical allodynia
Following neuropathic surgery, the mechanical threshold was
measured on PODs 1, 4, and 7 (Fig. 1A). Prior to surgery, animals in the
neuropathic (NP) and sham-injured (Sham) groups exhibited no dif-
ferences in the threshold. However, the mechanical threshold of the NP
group was significantly decreased following surgery relative to the
sham group (Fig. 1B).
3.2. Microinjection of Torin1 or XL388 into the IC attenuates neuropathic
pain
The pain-relieving effects of Torin1 and XL388 were assessed. On
POD 7, the vehicle (0.06 % DMSO in saline, 0.5 μl), Torin1 (400 nM,
0.5 μl), or XL388 (500 nM, 0.5 μl) was administered into the IC of
neuropathic rats. Mechanical thresholds were measured 0.5, 1, 2, 4, 8,
12, 24, and 48 h following injection (Fig. 2). The most substantial at-
tenuation effects of Torin1 and XL388 were observed 4 h following the
microinjection. Significant analgesic effects of Torin1 and XL388 were
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observed at 1–8 h and 4–12 h after microinjection, respectively (Fig. 2).
By 24 h after the microinjection, the withdrawal thresholds of the
Torin1- and XL388-injected groups had decreased and resembled those
of the vehicle group.
3.3. Torin1 and XL388 downregulate mTORC1 downstream targets
Immunoblotting was performed using samples collected 4 h fol-
lowing microinjection, corresponding to the timing of the highest pain
alleviation effect. The vehicle control group exhibited increased levels
of phosphorylated mTOR (p-mTOR) relative to the sham controls
(Fig. 3A). Administration of Torin1 or XL388 reversed this effect, de-
creasing p-mTOR abundance to levels below those observed in the ve-
hicle group. Similarly, the levels of phosphorylated 4E-BP1 (p-4E-BP1)
were significantly increased in the vehicle-injected group (Fig. 3B). The
Torin1- and XL388-treated groups exhibited lower levels of p-4E-BP1
relative to the vehicle-injected group. Neuropathic injury was also as-
sociated with elevated levels of phosphorylated p70S6K (p-p70S6K),
with this increase suppressed by Torin1 or XL388 administration
(Fig. 3C).
3.4. Microinjection of Torin1 and XL388 into the IC alters mTORC2
downstream targets
We measured the phosphorylation levels of PKCα and Akt in neu-
ropathic rats following Torin1 or XL388 administration. Levels of
phosphorylated PKCα (p-PKCα) were increased in the vehicle-injected
group relative to the sham group. However, rats injected with Torin1 or
XL388 showed a significant decrease in p-PKCα levels compared to rats
injected with the vehicle control (Fig. 4A). The levels of phosphorylated
Akt (p-Akt) showed a significant increase in the vehicle group com-
pared to the sham injury group. However, no significant differences
were observed in p-Akt expressions in the Torin1- and XL388-treated
groups compared to the vehicle (Fig. 4B).
4. Discussion
In this study, we demonstrated the pain alleviation effect of Torin1
and XL388. We examined the inhibition of mTORC1 as well as of
mTORC2 to confirm the pain alleviation effect of the mTOR signaling
pathway in the IC. After the administration of Torin1 or XL388, the
mechanical allodynia was significantly decreased and the activity of
mTOR complexes and their downstream effectors was significantly re-
duced.
In the process of pain-related neural plasticity, mTOR kinase is one
of the key factors related to protein synthesis [10]. In the present study,
a significant increase in p-mTOR was shown in the nerve-injured group.
This result is consistent with other studies, including our previous
studies, showing increased phosphorylation of mTOR following nerve
injury [7,23,27], and it indicates that the protein synthesis involved in
neural plasticity causing neuropathic pain is increased. The decline in
mechanical allodynia after administration of Torin1 or XL388 suggests
that the mTOR-mediated plasticity was decreased.
We have examined the changes in the phosphorylation of mTOR
complexes by measuring activated individual substrates. Each mTOR
complex phosphorylates corresponding downstream effectors [28,29].
Activated 4E-BP1 and p70S6K can trigger de novo proteins synthesis
[14]. One of the processes that require de novo protein synthesis is the
alteration of neuroplasticity that develops in chronic neuropathy con-
ditions [30]. Local protein synthesis via 4E-BP1 and p70S6K has been
reported to affect nociceptive function [31], and deletion of the
mTORC1 downstream effectors has resulted in a deficiency of long-term
memory [32,33]. mTORC1 related to translation factors such as 4E-BP1
and p70S6K has been studied in some cortical regions involved in pain
processing in our previous studies [7,27]. p-4E-BP1 and p-p70S6K were
increased under chronic pain conditions, and mechanical allodynia was
Fig. 1. Assessment of hind-paw mechanical withdrawal threshold following
nerve injury. (A) Schematic diagram of the experimental procedure, indicating
timing of behavioral testing and neuropathic surgery. (B) Changes in the
withdrawal threshold in neuropathic (NP; n= 24) and sham-injured (Sham;
n= 8) groups, as measured prior to the surgical procedures and on post-op-
erative days (PODs) 1, 4, and 7. Data are presented as means ± SEM, ***
p < 0.001 vs. sham, as determined using a two-way repeated measures ana-
lysis of variance (ANOVA) followed by the Bonferroni’s post-hoc multiple
comparison test.
Fig. 2. Changes in hind-paw withdrawal thresholds after microinjection of
vehicle (n= 8), Torin1 (n= 8), or XL388 (n=8) on POD 7. Data are presented
as means ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. vehicle, as
determined using a two-way ANOVA followed by the Bonferroni’s post-hoc
multiple comparison test.
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attenuated when these translation factors were inhibited. In line with
our previous studies [7,27], we observed an increase in p-4E-BP1 and p-
p70S6K in the vehicle group, implying that protein synthesis required
for LTP accompanied by the development of neuropathic pain was
elevated. Conversely, a significant decrease in p-4E-BP1 and p-S6K in
the Torin1- and XL388-treatment groups was attributed to the relief of
neuropathic pain by inhibiting protein synthesis involved in neural
plasticity.
In our results, p-PKCα was increased in the nerve-injured group and
was reversed in the group that was treated with Torin1 or XL388. Many
studies have confirmed activation of PKCα, which follows mTORC2
phosphorylation [29,34]. PKCα is known to play a critical role in the
cytoskeleton rearrangement induced by mTORC2 [15]. Moreover,
down-regulation of the PKCα generates an abnormal cell shape or ex-
cessive actin cytoskeleton and it alters neurons by rearranging their
configuration, volume, or length [28]. Such changes in the shape or
dimensions of existing neurons could affect neuronal plasticity [35].
Based on previous studies, our results suggest that the cytoskeleton-
associated plasticity was impeded by Torin1 and XL388.
Akt, another important factor related to mTORC2, is a crucial factor
involved in both mTORC1 and mTORC2 signaling [17,30]. Akt has been
reported to be involved in neuronal plasticity [36], and Akt-mediated
hypersensitivity studies have been conducted in various hyperalgesia
animal models such as spinal nerve ligation-induced hyperalgesia or
carrageen- and capsaicin-induced hypersensitivity [36–39]. In our re-
sults, p-Akt was increased in the vehicle-treated group compared to the
sham group. This result was consistent with the significant increase in
p-Akt in the spinal dorsal horn (SDH) and dorsal root ganglion observed
on the spinal nerve ligation-induced neuropathic pain model [37].
Therefore, we speculated that the increased p-Akt in the vehicle group
was due to the upregulated phosphorylation of mTORC1/2 caused by
nerve injury. In the Torin1- and XL388-treated groups, p-Akt tended to
decrease compared to the vehicle group, but the difference was not
statistically significant. According to studies on mTORC1/2 inhibition,
Torin1 and XL388 decrease p-Akt in addition to arresting pathological
cell growth [22,23]. These results, which differ from those of our study,
might be due to the different cell types in in vitro studies in which ab-
normal cell growth and cell activity were suppressed in tumor cells, but
not in nerve tissues [22,24]. Among other possibilities, the inhibition of
p-Akt, which was increased by hyperalgesia, might be time-dependently
changed. After spinal nerve ligation, p-Akt was significantly increased
in the SDH. However, the inhibition of p-Akt on 3 or 7 days after nerve
ligation had no pain alleviation effect [37]. In line with this finding, we
speculated that the downregulation of p-Akt may not be significant in
Torin1 and XL388-treated groups, since the drugs were injected 7 days
after nerve injury. As another possibility, various feedback loops of Akt
may have influenced p-Akt expression in the drug-treated groups with
Torin1 and XL388. Akt is associated with a feedback loop through
phosphatidylinositol 3-dependent kinase-1 (PDK1) that is enhanced by
inhibiting the phosphorylation of mTOR [34,40], and may also be af-
fected by its own feedback loop which regulates the phosphorylation of
Akt depending on the levels of phosphorylation at different phosphate
sites such as Ser 473 and Thr308 [41,42]. Furthermore, Torin1 and
XL388 may not significantly reduce p-Akt due to the limitation of
Fig. 3. Microinjection of Torin1 and XL388 into the IC reverses upregulation of p-mTOR and of mTORC1 downstream signaling. Levels of phosphorylated (p-) mTOR
(A), p-4E-BP1 (B), and p-p70S6K (C) relative to the total form were assessed with immunoblotting. Data are presented as means ± SEM. ** p < 0.01 vs. Sham, #
p < 0.05, ## p < 0.01, ### p < 0.001 vs. vehicle, as determined using a one-way ANOVA followed by the Bonferroni’s post-hoc multiple comparison test.
Fig. 4. Microinjection of Torin1 and XL388
into the IC modulates mTORC1/2 downstream
effectors. Levels of phosphorylated (p-) PKCα
(A) and p-Akt (B) relative to the total form
were assessed with immunoblotting. Data are
presented as means ± SEM. * p < 0.05 vs.
sham, ## p < 0.01, ### p < 0.001 vs. ve-
hicle, as determined using a one-way ANOVA
followed by the Bonferroni’s post-hoc multiple
comparison test.
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potency that can only partially inhibit PI3K [22,43]. In line with pre-
vious studies, Torin1 and XL388 could inhibit the activation of
mTORC2. However, the expression levels of p-Akt may be affected by
factors other than mTORC2 in neuropathic pain rats. Further studies are
required to shed light on the alleviation of neuropathic pain that in-
volves Akt signaling.
Torin1 and XL388 mainly inhibit phosphorylation of both mTOR
complexes. However, they differ in their molecular shapes and affect
different factors such as PI3K and phosphatidylinositol 3-kinase-related
kinase (PIKK) family, which are related to the mTOR pathway [44]. We
tried to assess the potential differences in the effects of Torin1 and
XL388 on pain alleviation and mTOR downstream effectors. However,
we could not observe significant difference in the extent of pain at-
tenuation effect between Torin1 and XL388, and there were no sig-
nificant differences in the expression levels of mTOR substrates.
In this study, we extended the research on pain-related mTOR sig-
naling in the brain by studying the effect of mTORC1/2 inhibition.
Compared to our previous study, which demonstrated a pain alleviation
effect when rapamycin was injected directly into the IC [7], simulta-
neous inhibition of mTORC1/2 with Torin1 or XL388 did not appear to
be more effective. The reversed mechanical withdrawal thresholds as
well as the changes in expressions of downstream targets of mTORC1 in
the two studies were comparable. Moreover, pain attenuation effect
was observed without a significant decrease in p-Akt, which is a pivotal
sub-factor of mTORC2. A recent study [23] examined the pain alle-
viation effect by using an mTORC1 inhibitor and Torin1. Two groups
treated by intraperitoneal administration of an mTORC1 inhibitor or
Torin1 were found to show effective inhibition of mechanical and cold
hypersensitivity. However, the analgesic effect of Torin1-injected group
did not have a superior effect compared to that of the mTORC1 in-
hibitor group [23]. In line with this research and our findings, relieving
neuropathic pain by suppressing both mTOR complexes seemed clearly
effective. However, we speculate that mTORC2 may not be a key at-
tributor in the transient pain alleviation. Drugs that can chemically
inhibit only mTOC2 phosphorylation have not yet been developed, and
it is difficult to confirm the role of individual complexes that modulate
pain. To determine the role of mTORC2 in pain control, more detailed
future studies that target mTORC2 and rictor-specific inhibition af-
fecting mTORC2 functions are needed.
5. Conclusion
We investigated the pain-relieving effects of mTOR inhibition using
Torin1 and XL388 in the IC. We found that inhibition of mTORC1/2
reduces mechanical allodynia and modulates the downstream effectors
of mTORC1/2 in the IC. Our behavioral and molecular data may con-
tribute to establishing novel approaches for pain control in chronic
neuropathy.
Conflicts of interest
The authors declare no conflict of interest.
CRediT authorship contribution statement
Songyeon Choi: Methodology, Validation, Formal analysis,
Investigation, Writing - original draft, Writing - review & editing.
Kyeongmin Kim: Methodology, Validation, Formal analysis, Writing -
original draft, Data curation, Writing - review & editing.
Myeounghoon Cha: Conceptualization, Methodology, Validation,
Investigation, Supervision, Project administration, Funding acquisition.
Minjee Kim: Formal analysis, Data curation. Bae Hwan Lee:
Conceptualization, Supervision, Project administration, Funding ac-
quisition.
Acknowledgements
This work was supported by a National Research Foundation of
Korea (NRF) grant funded by the Korea government (MSIT) (No.
2017R1A2B3005753).
References
[1] L.S. Ro, K.H. Chang, Neuropathic pain: mechanisms and treatments, Chang Gung
Med. J. 28 (2005) 597–605.
[2] M.C. Bushnell, M. Ceko, L.A. Low, Cognitive and emotional control of pain and its
disruption in chronic pain, Nat. Rev. Neurosci. 14 (2013) 502–511.
[3] C. Lu, T. Yang, H. Zhao, M. Zhang, F. Meng, H. Fu, Y. Xie, H. Xu, Insular cortex is
critical for the perception, modulation, and chronification of pain, Neurosci. Bull.
32 (2016) 191–201.
[4] A.S. Jaggi, N. Singh, Role of different brain areas in peripheral nerve injury-induced
neuropathic pain, Brain Res. 1381 (2011) 187–201.
[5] X.H. Li, H.H. Miao, M. Zhuo, NMDA receptor dependent long-term potentiation in
chronic pain, Neurochem. Res. (2018) 531–538.
[6] J. Han, M. Kwon, M. Cha, M. Tanioka, S.K. Hong, S.J. Bai, B.H. Lee, Plasticity-
related PKMzeta signaling in the insular cortex is involved in the modulation of
neuropathic pain after nerve injury, Neural Plast. 2015 (2015) 601767.
[7] M. Kwon, J. Han, U.J. Kim, M. Cha, S.W. Um, S.J. Bai, S.-K. Hong, B.H. Lee,
Inhibition of mammalian target of rapamycin (mTOR) signaling in the insular
cortex alleviates neuropathic pain after peripheral nerve injury, Front. Mol.
Neurosci. 10 (2017).
[8] M. Laplante, D.M. Sabatini, mTOR signaling in growth control and disease, Cell 149
(2012) 274–293.
[9] N. Hay, N. Sonenberg, Upstream and downstream of mTOR, Genes Dev. 18 (2004)
1926–1945.
[10] C.A. Hoeffer, E. Klann, mTOR signaling: at the crossroads of plasticity, memory and
disease, Trends Neurosci. 33 (2010) 67–75.
[11] J. Jaworski, M. Sheng, The growing role of mTOR in neuronal development and
plasticity, Mol. Neurobiol. 34 (2006) 205–219.
[12] X. Wang, C.G. Proud, The mTOR pathway in the control of protein synthesis,
Physiology 21 (2006) 362–369.
[13] M. Costa-Mattioli, W.S. Sossin, E. Klann, N. Sonenberg, Translational control of
long-lasting synaptic plasticity and memory, Neuron 61 (2009) 10–26.
[14] R.J. Kelleher 3rd, A. Govindarajan, S. Tonegawa, Translational regulatory me-
chanisms in persistent forms of synaptic plasticity, Neuron 44 (2004) 59–73.
[15] W.J. Oh, E. Jacinto, mTOR complex 2 signaling and functions, Cell Cycle 10 (2011)
2305–2316.
[16] Z. Jiang, S. Wu, X. Wu, J. Zhong, A. Lv, J. Jiao, Z. Chen, Blocking mammalian target
of rapamycin alleviates bone cancer pain and morphine tolerance via μ-opioid re-
ceptor, Int. J. Cancer 138 (2016) 2013–2020.
[17] M.H. Shih, S.C. Kao, W. Wang, M. Yaster, Y.X. Tao, Spinal cord NMDA receptor-
mediated activation of mammalian target of rapamycin is required for the devel-
opment and maintenance of bone cancer-induced pain hypersensitivities in rats, J.
Pain 13 (2012) 338–349.
[18] A.M. Martelli, F. Buontempo, J.A. McCubrey, Drug discovery targeting the mTOR
pathway, Clin. Sci. 132 (2018) 543–568.
[19] D.A. Guertin, D.M. Sabatini, The pharmacology of mTOR inhibition, Sci. Signal. 2
(2009) 24.
[20] Z. Xiong, Y. Zang, S. Zhong, L. Zou, Y. Wu, S. Liu, Z. Fang, Z. Shen, Q. Ding, S. Chen,
The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-
renal cell carcinoma agent, Oncotarget 8 (2017) 30151–30161.
[21] Y.R. Zhu, X.Z. Zhou, L.Q. Zhu, C. Yao, J.F. Fang, F. Zhou, X.W. Deng, Y.Q. Zhang,
The anti-cancer activity of the mTORC1/2 dual inhibitor XL388 in preclinical os-
teosarcoma models, Oncotarget 7 (2016) 49527–49538.
[22] Q. Liu, S.A. Kang, C.C. Thoreen, W. Hur, J. Wang, J.W. Chang, A. Markhard,
J. Zhang, T. Sim, D.M. Sabatini, N.S. Gray, Development of ATP-competitive mTOR
inhibitors, Methods Mol. Biol. 821 (2012) 447–460.
[23] I. Obara, K.K. Tochiki, S.M. Geranton, F.B. Carr, B.M. Lumb, Q. Liu, S.P. Hunt,
Systemic inhibition of the mammalian target of rapamycin (mTOR) pathway re-
duces neuropathic pain in mice, Pain 152 (2011) 2582–2595.
[24] C. Cho, V. Michailidis, L.J. Martin, Revealing brain mechanisms of mTOR-mediated
translational regulation: implications for chronic pain, Neurobiol. Pain 4 (2018)
27–34.
[25] B.H. Lee, R. Won, E.J. Baik, S.H. Lee, C.H. Moon, An animal model of neuropathic
pain employing injury to the sciatic nerve branches, Neuroreport 11 (2000)
657–661.
[26] N.-T. Cheng, A. Guo, Y.-P. Cui, Intra-articular injection of Torin 1 reduces degen-
eration of articular cartilage in a rabbit osteoarthritis model, Bone Joint Res. 5
(2016) 218–224.
[27] S.W. Um, M.J. Kim, J.W. Leem, S.J. Bai, B.H. Lee, Pain-relieving effects of mTOR
inhibitor in the anterior cingulate cortex of neuropathic rats, Mol. Neurobiol. 56
(2018) 2482–2494.
[28] D.D. Sarbassov, S.M. Ali, D.H. Kim, D.A. Guertin, R.R. Latek, H. Erdjument-
Bromage, P. Tempst, D.M. Sabatini, Rictor, a novel binding partner of mTOR, de-
fines a rapamycin-insensitive and raptor-independent pathway that regulates the
cytoskeleton, Curr. Biol. 14 (2004) 1296–1302.
[29] V. Facchinetti, W. Ouyang, H. Wei, N. Soto, A. Lazorchak, C. Gould, C. Lowry,
A.C. Newton, Y. Mao, R.Q. Miao, W.C. Sessa, J. Qin, P. Zhang, B. Su, E. Jacinto, The
S. Choi, et al. Neuroscience Letters 718 (2020) 134742
5
mammalian target of rapamycin complex 2 controls folding and stability of Akt and
protein kinase C, EMBO J. 27 (2008) 1932–1943.
[30] B. Xu, G. Descalzi, H.R. Ye, M. Zhuo, Y.W. Wang, Translational investigation and
treatment of neuropathic pain, Mol. Pain 8 (2012) 15.
[31] L. Lisi, P. Aceto, P. Navarra, C. Dello Russo, mTOR kinase: a possible pharmaco-
logical target in the management of chronic pain, Biomed Res. Int. 2015 (2015)
394257.
[32] S. Barak, F. Liu, S.B. Hamida, Q.V. Yowell, J. Neasta, V. Kharazia, P.H. Janak,
D. Ron, Disruption of alcohol-related memories by mTORC1 inhibition prevents
relapse, Nat. Neurosci. 16 (2013) 1111.
[33] A. Deli, K. Schipany, M. Rosner, H. Höger, A. Pollak, L. Li, M. Hengstschläger,
G. Lubec, Blocking mTORC1 activity by rapamycin leads to impairment of spatial
memory retrieval but not acquisition in C57BL/6J mice, Behav. Brain Res. 229
(2012) 320–324.
[34] C. Gaubitz, M. Prouteau, B. Kusmider, R. Loewith, TORC2 structure and function,
Trends Biochem. Sci. 41 (2016) 532–545.
[35] H.K. Lee, Synaptic plasticity and phosphorylation, Pharmacol. Ther. 112 (2006)
810–832.
[36] S.P. Chen, Y.Q. Zhou, D.Q. Liu, W. Zhang, A. Manyande, X.H. Guan, Y.K. Tian,
D.W. Ye, D.M. Omar, PI3K/Akt pathway: a potential therapeutic target for chronic
pain, Curr. Pharm. Des. 23 (2017) 1860–1868.
[37] J.-T. Xu, H.-Y. Tu, W.-J. Xin, X.-G. Liu, G.-H. Zhang, C.-H. Zhai, Activation of
phosphatidylinositol 3-kinase and protein kinase B/Akt in dorsal root ganglia and
spinal cord contributes to the neuropathic pain induced by spinal nerve ligation in
rats, Exp. Neurol. 206 (2007) 269–279.
[38] B. Xu, X.-H. Guan, J.-X. Yu, J. Lv, H.-X. Zhang, Q.-C. Fu, H.-B. Xiang, H.-L. Bu,
D. Shi, B. Shu, L.-S. Qin, A. Manyande, Y.-K. Tian, Activation of spinal phosphati-
dylinositol 3-kinase/protein kinase B mediates pain behavior induced by plantar
incision in mice, Exp. Neurol. 255 (2014) 71–82.
[39] R.Q. Sun, Y.J. Tu, J.Y. Yan, W.D. Willis, Activation of protein kinase B/Akt signaling
pathway contributes to mechanical hypersensitivity induced by capsaicin, Pain 120
(2006) 86–96.
[40] P.T. Bhaskar, N. Hay, The two TORCs and akt, Dev. Cell 12 (2007) 487–502.
[41] G. Yang, D.S. Murashige, S.J. Humphrey, D.E. James, A positive feedback loop
between Akt and mTORC2 via SIN1 phosphorylation, Cell Rep. 12 (2015) 937–943.
[42] D.D. Sarbassov, D.A. Guertin, S.M. Ali, D.M. Sabatini, Phosphorylation and reg-
ulation of Akt/PKB by the rictor-mTOR complex, Science 307 (2005) 1098–1101.
[43] C.S. Takeuchi, B.G. Kim, C.M. Blazey, S. Ma, H.W. Johnson, N.K. Anand, A. Arcalas,
T.G. Baik, C.A. Buhr, J. Cannoy, S. Epshteyn, A. Joshi, K. Lara, M.S. Lee, L. Wang,
J.W. Leahy, J.M. Nuss, N. Aay, R. Aoyama, P. Foster, J. Lee, I. Lehoux, N. Munagala,
A. Plonowski, S. Rajan, J. Woolfrey, K. Yamaguchi, P. Lamb, N. Miller, Discovery of
a novel class of highly potent, selective, ATP-competitive, and orally bioavailable
inhibitors of the mammalian target of rapamycin (mTOR), J. Med. Chem. 56 (2013)
2218–2234.
[44] S. Albert, M. Serova, C. Dreyer, M.P. Sablin, S. Faivre, E. Raymond, New inhibitors
of the mammalian target of rapamycin signaling pathway for cancer, Expert Opin.
Investig. Drugs 19 (2010) 919–930.
S. Choi, et al. Neuroscience Letters 718 (2020) 134742
6
